Sema4 to Buy GeneDx for $623M

AI-driven genomic and clinical data intelligence platform company Sema4 signed an agreement where Sema4 will acquire multinational biopharma and diagnostics firm OPKO Health’s subsidiary GeneDx. GeneDx provides genomic testing and analysis, and will strengthen Sema4’s growth with health intelligence and genomic screening offerings. The combined company will be considered one of the largest providers of genomic clinical testing in the U.S.
 
The approximate purchase price is $623 million.
 
GeneDx offers leadership in rare disease diagnostic and exome sequencing, bringing over 300,000 clinical exomes and over 2.1 million phenotypes to bolster Sema4’s 12 million de-identified clinical records for Centrellis, its health intelligence platform. It will also augment Travera, Sema4’s comprehensive genomic analysis platform.
 
“This acquisition gives us the opportunity to accelerate the use of genomics as standard of care by providing a deeper menu of precision medicine solutions to our health system partners to better meet their clinical needs,” Eric Schadt, Ph.D., founder, and CEO of Sema4 told the press. “Adding GeneDx’s comprehensive dataset and capabilities to our offerings enables us to inform on an even broader range of diseases, further closing the gap between the practice of medicine and the availability of more clinically actionable guidance. GeneDx’s operational prowess and market-leading cost structure in exome and genome sequencing will also help accelerate our path to improved gross margins and profitability. I am also delighted to welcome Katherine to our leadership team. She and her team’s world-class expertise will be critical to our continued growth and success.”
 
GeneDx president and CEO Katherine Stueland will be appointed as Sema4 co-CEO and appointed to the Board of Directors.
 
“We are excited to join forces with Sema4, a market leader in using genomic and clinical data to deliver precision medicine,” said Stueland. “The complementary fit between our teams, missions, and capabilities is strong. We are eager to put those strengths to work and to make it easier to use data-driven insights to improve healthcare for all. I’m looking forward to partnering with Eric to create an unrivaled family health and health intelligence company, supporting patients making healthcare decisions throughout their lives, from pregnancy and newborn health to adult rare disease, risk assessment, and cancer care.”
 
Part of the transaction involves Sema4 agreeing to $200 million private placement of Sema4 shares from institutional investors, including Pfizer. The acquisition and private placement are expected to close in the second quarter of this year.
 
Phillip Frost, M.D., Chairman and CEO of OPKO, added, “We believe the sale of GeneDx to Sema4 will unlock untapped value and maximize the value of GeneDx for the benefit of OPKO shareholders. In addition to bolstering our cash position, we will have a significant equity stake in Sema4 at closing, ensuring OPKO and our shareholders continue to participate in the rapidly growing genomics market through a continued investment in GeneDx, which we believe is well positioned to deliver long-term success.”